FDA Approval for LIVSAYIS issued to REGENERON PHARMACEUTICALS

The FDA approved Regeneron Pharmaceuticals' LIVSAYIS (cemdisiran) on 11/18/2026 under a priority-review NDA. The drug is a new molecular entity with a single-dose vial strength of 189 mg/mL. The approval confirms a new drug has cleared FDA review, though no sales or revenue expectations were stated.

Original reporting
Published Nov 19, 2026, 12:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 1:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$REGN
Bullish
medium confidence
Mentioned
$REGN
Relevance
7/10
AlphAI data visualization · based on quantisnow.com
Decision brief

The 30-second read

$REGNBullishMed
01

Why it matters

This is a de-risking regulatory event for Regeneron’s drug candidate, typically improving probability-weighted future cash flows, though the article does not quantify commercial impact.

02

Market read

Traders can treat this as a fresh regulatory catalyst for REGN, but should note the lack of commercialization or financial guidance in the text.

03

What to watch

Key missing details include indication, trial endpoints, pricing/reimbursement dynamics, and whether the approval enables immediate commercialization or requires additional steps.

Relevance 7/10Novelty 8/10Timing: FDA approval dated 11/18/2026, reported on 11/19/2026

Background

The article states FDA approval of Regeneron’s LIVSAYIS (cemdisiran) under NDA 221251, classified as a Type 1 New Molecular Entity with priority review.

Company-level read

Ticker impact

$REGNBullishMedium confidence
Context

FDA approved Regeneron’s LIVSAYIS (cemdisiran) on 11/18/2026 as a priority-review NDA for a new molecular entity.

Expected impact

Likely upward bias as the market prices in reduced regulatory risk and potential future revenue optionality.

Evidence & confidence

The text is a first-order FDA approval event for the company’s drug, which typically supports sentiment; however, absence of sales expectations or label details beyond strength limits near-term earnings impact visibility.

Market effects

Supports biotech sentiment around siRNA therapeutics and FDA willingness to grant priority review for new molecular entities.

Primarily US-focused regulatory catalyst; could spill into broader US biotech risk appetite.

Limited direct global read-through in the article, but FDA approvals can influence international investor positioning in similar modalities.

Counterpoint

Without any disclosed launch timing, uptake data, or revenue expectations, the stock reaction may fade as investors refocus on pipeline depth and commercialization execution.

Key entities

  • Regeneron Pharmaceuticals Inc.

    Issuer of LIVSAYIS (cemdisiran), whose NDA was approved by the FDA on 11/18/2026.

  • LIVSAYIS (cemdisiran)

    Single-dose vial drug product approved under NDA 221251; strength listed as 189 mg/mL.

  • FDA

    Approved the New Drug Application (NDA 221251) with priority review classification.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$REGNHigh

Argus raises Regeneron stock price target on Dupixent strength

Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$REGNMed

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

The European Commission approved an extended dosing schedule for cemiplimab (Libtayo), a cancer drug by Regeneron Pharmaceuticals, across all approved indications in skin, lung, and cervical cancers. The new schedule allows 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks, with shorter infusion times. The decision follows a positive opinion from the European Medicines Agency. According to Regeneron, this aims to reduce patient burden and increase healthcare flexibility.

$REGNMed

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.

$REGNMed

REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis

Regeneron Pharmaceuticals received FDA approval for Livsayis, a siRNA therapy for generalized myasthenia gravis (gMG). It is the first of its kind and is administered subcutaneously four times a year. The approval was based on positive phase III NIMBLE study results, showing significant symptom improvement. Livsayis carries a Boxed Warning for serious infections. Regeneron's stock has risen 22.9% year-to-date. The therapy is under review in the EU and planned for other regions.